Skip to content

Matthew K. Nock

15 papers in the library · 526 citations · publishing 2009-2024

Papers

Sort Most recent Most cited

Race and ethnicity moderate the associations between lifetime psilocybin use and past year hypertension

Frontiers in Psychiatry June 24, 2024 Grant Jones, Jocelyn A. Ricard, Matthew K. Nock 5 citations

Background Hypertension is a major source of morbidity and mortality worldwide, particularly for racial and ethnic minorities who face higher rates of hypertension and worse health-related outcomes. Recent research has reported on protective associations between classic psychedelics and hypertension; however, there is a need to explore how race and ethnicity may moderate such associations....

DOI: 10.3389/fpsyt.2024.1169686 (opens in new tab) Nsduh Race Drug epidemiology Psilocybin research +3

Race and ethnicity moderate the associations between lifetime psilocybin use and crime arrests

Frontiers in Psychiatry August 24, 2023 Grant Jones, Patrick Mair, Maha Al-Suwaidi et al. 10 citations

Introduction Psilocybin use has been linked to lowered odds of crime-related outcomes across a host of observational studies. No studies have investigated how these associations may differ among those of different races and ethnicities. Methods Using a nationally-representative sample of 734,061 adults from the National Survey on Drug Use and Health (2002–2020), we investigated whether race and...

DOI: 10.3389/fpsyt.2023.1169692 (opens in new tab) Psilocybin Ethnic group Race biology Mental health +6

A Digital Music-Based Mindfulness Intervention for Black Americans With Elevated Race-Based Anxiety: A Multiple-Baseline Pilot Study.

JMIR Formative Research August 16, 2023 Grant Jones, Felipe Herrmann, Matthew K. Nock 7 citations

Race-based anxiety is a substantial health issue for the Black community. Although mindfulness interventions have demonstrated efficacy for alleviating anxiety, three central barriers prevent Black Americans from accessing existing mindfulness treatments: high costs, excessive time commitments, and limited cultural relevance. There is a need for novel mindfulness interventions for the Black...

Associations between MDMA/ecstasy, classic psychedelics, and suicidal thoughts and behaviors in a sample of U.S. adolescents.

Scientific Reports December 19, 2022 Grant Jones, Diego Arias, Matthew K. Nock 18 citations

Suicide is one of the leading causes of death amongst adolescents and decades of research have failed to curb suicide rates within this population. There is thus a need to better understand factors that correlate with adolescent suicidal thoughts and behaviors (STBs). MDMA/ecstasy and classic psychedelics represent two areas for exploration, as use of these substances has been associated with...

Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA and psilocybin) and psychological distress and suicidality.

Scientific Reports October 10, 2022 Grant Jones, Matthew K. Nock 46 citations

Psychedelic compounds have been linked to salutary mental health outcomes in both naturalistic and clinical settings; however, current research on psychedelics suffers from a lack of inclusion and focus on racial and ethnic minorities. Thus, the goal of our study was to assess whether race and ethnicity moderate the associations that naturalistic lifetime MDMA...

DOI: 10.1038/s41598-022-18645-3 (opens in new tab) Full text (opens in new tab) Psychedelics Mental health Racial disparities Clinical research +1

Associations between classic psychedelics and nicotine dependence in a nationally representative sample

Scientific Reports June 22, 2022 Grant Jones, Joshua Lipson, Matthew K. Nock 31 citations

Abstract Tobacco use is the single largest cause of preventable death worldwide, but none of the established treatments aimed at smoking cessation work for a majority of smokers. As such, there is an urgent need for interventions capable of reliably treating nicotine addiction. The use of classic psychedelics has been associated with lower odds of many forms of substance dependence. Here we...

Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample

Scientific Reports April 7, 2022 Grant Jones, Jocelyn A. Ricard, Joshua Lipson et al. 56 citations

Abstract Opioid use disorder (OUD) is a major source of morbidity and mortality in the U.S. and there is a pressing need to identify additional treatments for the disorder. Classic psychedelics (psilocybin, peyote, mescaline, LSD) have been linked to the alleviation of various substance use disorders and may hold promise as potential treatments for OUD. The aim of this study was to assess...

Exploring protective associations between the use of classic psychedelics and cocaine use disorder: a population-based survey study

Scientific Reports February 16, 2022 Grant Jones, Matthew K. Nock 44 citations

Abstract Cocaine Use Disorder (CUD) is a significant public health problem associated with elevated morbidity and mortality within the United States. Current behavioral treatments have limited efficacy and there are currently no FDA approved pharmacological treatments for CUD. Classic psychedelics might be associated with lowered odds of substance misuse and may effectively treat various forms...

MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults

Journal of Psychopharmacology 2022 Grant Jones, Matthew K. Nock 60 citations

Background: Suicide is one of the leading causes of death worldwide and rates within the United States have risen over the past two decades. Hence, there is a critical need for novel tools to treat suicidal ideation and related mental health conditions. 3,4-Methylenedioxymethamphetamine (MDMA)/ecstasy and classic psychedelics may be two such tools. Aims: The aim of this study was to assess...

Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes

Journal of Psychopharmacology 2022 Grant Jones, Matthew K. Nock 40 citations

Background: Depression is a major mental health issue worldwide, with high rates of chronicity and non-recovery associated with the condition. Existing treatments such as antidepressant medication and psychological treatments have modest effectiveness, suggesting the need for alternative interventions. Aim: The aim of this study was to examine the relationships between MDMA...

Psilocybin use is associated with lowered odds of crime arrests in US adults: A replication and extension

Journal of Psychopharmacology 2022 Grant Jones, Matthew K. Nock 30 citations

Background: The United States boasts the largest prison population in the world, conferring significant direct and indirect costs (e.g. lost wages for the incarcerated, increased morbidity/mortality, etc.) to society. Recidivism rates are high for the imprisoned and most interventions to reduce criminality are minimally effective. Thus, in addition to the need for criminal justice reform, there...

Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial.

Journal of Affective Disorders 2019 Dawn F. Ionescu, Kate H Bentley, M. Eikermann et al. 179 citations

BACKGROUND Several studies indicate that ketamine has rapid antidepressant effects in patients with treatment-resistant depression (TRD). The extent to which repeated doses of ketamine (versus placebo) reduce depression in the short and long term among outpatients with TRD and chronic, current suicidal ideation remains unknown. METHODS Twenty-six medicated outpatients with severe major...

Rapid and Sustained Reductions in Current Suicidal Ideation Following Repeated Doses of Intravenous Ketamine: Secondary Analysis of an Open-Label Study.

The Journal of Clinical Psychiatry June 2016 Dawn F. Ionescu, Michaela B Swee, Kara J. Pavone et al.

Ketamine rapidly reduces thoughts of suicide in patients with treatment-resistant depression who are at low risk for suicide. However, the extent to which ketamine reduces thoughts of suicide in depressed patients with current suicidal ideation remains unknown. Between April 2012 and October 2013, 14 outpatients with DSM-IV-diagnosed major depressive disorder were recruited for the presence of...

Effects of Intravenous Ketamine on Explicit and Implicit Measures of Suicidality in Treatment-Resistant Depression

Biological Psychiatry July 9, 2009 R. Price, Matthew K. Nock, D. Charney et al.

Background Intravenous ketamine has shown rapid antidepressant effects in early trials, making it a potentially attractive candidate for depressed patients at imminent risk of suicide. The Implicit Association Test (IAT), a performance-based measure of association between two concepts, may have utility in suicide assessment. Methods Twenty-six patients with treatment-resistant depression were...

A Digital Music-Based Mindfulness Intervention for Black Americans With Elevated Race-Based Anxiety: A Multiple-Baseline Pilot Study (Preprint)

Grant Jones, Felipe Herrmann, Matthew K. Nock

BACKGROUND: Race-based anxiety is a substantial health issue for the Black community. Although mindfulness interventions have demonstrated efficacy for alleviating anxiety, three central barriers prevent Black Americans from accessing existing mindfulness treatments: high costs, excessive time commitments, and limited cultural relevance. There is a need for novel mindfulness interventions for...